Tapewire

Nasdaq · USD

ANIP

ANI PHARMACEUTICALS INC

Export transactions ↓
Tapewire entity
4638
SEC CIK
0001023024
Parsed reports
463

Last 12 months

Inside the activity.

0 purchase rows · 48 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202504
Dec 202503
Jan 202601
Feb 202605
Mar 2026012
Apr 202601
May 202606
Jun 202604
Jul 202603
Aug 202604
Sep 202604
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
April 16, 2024 Filed Apr 17, 2024 20:33 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 5,834 $66.20 $386,210.80
Disclosure

SEC source: 0001870913-24-000014 · wk-form4_1713385980.xml · nonDerivative · entry 3

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 819,372

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F4 · price: The shares were sold in multiple trades at prices ranging from $66.01 to $66.58. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 20:33 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 7,414 $66.33 $491,770.62
Disclosure

SEC source: 0001870913-24-000014 · wk-form4_1713385980.xml · nonDerivative · entry 2

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 825,206

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $65.65 to $67.27. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
April 12, 2024 Filed Apr 15, 2024 22:28 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 250 $67.79 $16,947.50
Disclosure

SEC source: 0001938861-24-000012 · wk-form4_1713220119.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,731

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 01:13 UTC
Marken James G.SVP OPS & PROD DEV
Tax withholdingCommon Stock 2,799 $66.96 $187,421.04
Disclosure

SEC source: 0001579587-24-000011 · wk-form4_1712884382.xml · nonDerivative · entry 1

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,006

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,137 shares of restricted stock, the grant of which was previously reported.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 01:12 UTC Tax withholdingCommon Stock 4,534 $66.96 $303,596.64
Disclosure

SEC source: 0001674236-24-000011 · wk-form4_1712884344.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,968

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 9,942 shares of restricted stock, the grant of which was previously reported.

Read SEC document
April 01, 2024 Filed Apr 2, 2024 22:59 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
SaleCommon Stock 20,000 $67.25 $1,345,000.00
Disclosure

SEC source: 0001871002-24-000008 · wk-form4_1712098747.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 253,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $66.50 to $69.05. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
March 23, 2024 Filed Mar 25, 2024 20:14 UTC
Marken James G.SVP OPS & PROD DEV
Tax withholdingCommon Stock 3,653 $69.58 $254,175.74
Disclosure

SEC source: 0001579587-24-000009 · wk-form4_1711397661.xml · nonDerivative · entry 1

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,805

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,010 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 23, 2024 Filed Mar 25, 2024 20:17 UTC Tax withholdingCommon Stock 6,210 $69.58 $432,091.80
Disclosure

SEC source: 0001674236-24-000009 · wk-form4_1711397817.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,502

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 13,618 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 23, 2024 Filed Mar 25, 2024 20:09 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 17,455 $69.58 $1,214,518.90
Disclosure

SEC source: 0001822629-24-000008 · wk-form4_1711397380.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,174

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 34,124 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 20:48 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
SaleCommon Stock 250 $66.54 $16,635.00
Disclosure

SEC source: 0001938861-24-000010 · wk-form4_1710362889.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,981

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
March 11, 2024 Filed Mar 11, 2024 22:39 UTC SaleCommon Stock 7,787 $65.55 $510,437.85
Disclosure

SEC source: 0001674236-24-000007 · wk-form4_1710196767.xml · nonDerivative · entry 2

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,712

F2 · price: The shares were sold in multiple trades at prices ranging from $65.08 to $66.63. The price reported above reflects the weighted average sales price.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:44 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
SaleCommon Stock 20,000 $65.81 $1,316,200.00
Disclosure

SEC source: 0001871002-24-000006 · wk-form4_1710362669.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 273,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $65.23 to $66.34. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
March 08, 2024 Filed Mar 9, 2024 00:25 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
SaleCommon Stock 16,292 $67.13 $1,093,681.96
Disclosure

SEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 3

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 411,629

F3 · price: The shares were sold in multiple trades at prices ranging from $66.42 to $67.74. The price reported above reflects the weighted average sales price.

Read SEC document
March 08, 2024 Filed Mar 11, 2024 22:43 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 10,000 $67.17 $671,700.00
Disclosure

SEC source: 0001870913-24-000012 · wk-form4_1710196991.xml · nonDerivative · entry 2

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 832,620

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $66.51 to $67.81, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 02:42 UTC
Marken James G.SVP OPS & PROD DEV
Tax withholdingCommon Stock 2,034 $66.71 $135,688.14
Disclosure

SEC source: 0001579587-24-000006 · wk-form4_1709865716.xml · nonDerivative · entry 2

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,458

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,644 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 02:42 UTC
Marken James G.SVP OPS & PROD DEV
SaleCommon Stock 24,338 $66.37 $1,615,313.06
Disclosure

SEC source: 0001579587-24-000006 · wk-form4_1709865716.xml · nonDerivative · entry 1

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,492

F1 · price: The shares were sold in multiple trades at prices ranging from $66.00 to $66.75. The price reported above reflects the weighted average sales price.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 02:21 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 2,494 $66.71 $166,374.74
Disclosure

SEC source: 0001846478-24-000009 · wk-form4_1709864464.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,212

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 02:16 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 2,110 $66.71 $140,758.10
Disclosure

SEC source: 0001846487-24-000010 · wk-form4_1709864200.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,277

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 02:11 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 15,085 $66.35 $1,000,889.75
Disclosure

SEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 4

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 842,620

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $65.53 to $67.00, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
March 07, 2024 Filed Mar 9, 2024 00:25 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 17,060 $66.71 $1,138,072.60
Disclosure

SEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 2

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427,921

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 22:39 UTC Tax withholdingCommon Stock 4,216 $66.71 $281,249.36
Disclosure

SEC source: 0001674236-24-000007 · wk-form4_1710196767.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,499

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,292 shares of restricted stock, the grant of which was previously reported.

Read SEC document
March 06, 2024 Filed Mar 8, 2024 02:11 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 14,822 $65.47 $970,396.34
Disclosure

SEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 3

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 857,705

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.84 to $66.04, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
March 06, 2024 Filed Mar 9, 2024 00:25 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
SaleCommon Stock 28,965 $65.52 $1,897,786.80
Disclosure

SEC source: 0001822629-24-000006 · wk-form4_1709943903.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,981

F1 · price: The shares were sold in multiple trades at prices ranging from $65.00 to $66.01. The price reported above reflects the weighted average sales price.

Read SEC document
March 05, 2024 Filed Mar 6, 2024 21:24 UTC
Mutz ChristopherHEAD OF RARE DISEASE
SaleCommon Stock 5,000 $66.00 $330,000.00
Disclosure

SEC source: 0001846487-24-000008 · wk-form4_1709760262.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,387

F1 · price: The shares were sold in multiple trades at prices ranging from $65.77 to $66.49. The price reported above reflects the weighted average sales price.

Read SEC document
March 05, 2024 Filed Mar 8, 2024 02:11 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
SaleCommon Stock 10,093 $65.35 $659,577.55
Disclosure

SEC source: 0001870913-24-000010 · wk-form4_1709863910.xml · nonDerivative · entry 2

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Esjay LLC

Disclosed balance after: 872,527

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.45 to $66.58, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 21:20 UTC SaleCommon Stock 7,000 $65.20 $456,400.00
Disclosure

SEC source: 0001689325-24-000002 · wk-form4_1709760008.xml · nonDerivative · entry 1

Pera Antonio R · CIK 0001689325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,627

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:18 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
Tax withholdingCommon Stock 1,122 $67.67 $75,925.74
Disclosure

SEC source: 0001870913-24-000008 · wk-form4_1709331498.xml · nonDerivative · entry 1

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,652

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:12 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 1,275 $67.67 $86,279.25
Disclosure

SEC source: 0001846487-24-000006 · wk-form4_1709331156.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,387

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:09 UTC
Marken James G.SVP OPS & PROD DEV
Tax withholdingCommon Stock 1,058 $67.67 $71,594.86
Disclosure

SEC source: 0001579587-24-000004 · wk-form4_1709330942.xml · nonDerivative · entry 1

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,830

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,256 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:06 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 10,014 $67.67 $677,647.38
Disclosure

SEC source: 0001822629-24-000004 · wk-form4_1709330802.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 473,946

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,882 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:03 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 1,570 $67.67 $106,241.90
Disclosure

SEC source: 0001846478-24-000007 · wk-form4_1709330627.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,706

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:01 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
Tax withholdingCommon Stock 1,635 $67.67 $110,640.45
Disclosure

SEC source: 0001871002-24-000004 · wk-form4_1709330494.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,679

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 21:59 UTC
Davis KristaSVP, CHIEF HR OFFICER
Tax withholdingCommon Stock 1,173 $67.67 $79,376.91
Disclosure

SEC source: 0001946439-24-000004 · wk-form4_1709330377.xml · nonDerivative · entry 1

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,545

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 21:57 UTC
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
Tax withholdingCommon Stock 1,173 $67.67 $79,376.91
Disclosure

SEC source: 0001938861-24-000008 · wk-form4_1709330246.xml · nonDerivative · entry 1

Cook Meredith · CIK 0001938861 · SR. VP, GENERAL COUNSEL & SEC.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,231

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,039 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 21:55 UTC Tax withholdingCommon Stock 1,914 $67.67 $129,520.38
Disclosure

SEC source: 0001674236-24-000005 · wk-form4_1709330090.xml · nonDerivative · entry 1

CAREY STEPHEN P. · CIK 0001674236 · SVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,715

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 22:09 UTC
Gutwerg OriSVP, GENERICS
Tax withholdingCommon Stock 1,244 $57.55 $71,592.20
Disclosure

SEC source: 0001846478-24-000005 · wk-form4_1708466883.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,276

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,227 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 22:02 UTC
Mutz ChristopherHEAD OF RARE DISEASE
Tax withholdingCommon Stock 1,261 $57.55 $72,570.55
Disclosure

SEC source: 0001846487-24-000004 · wk-form4_1708466458.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,662

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,034 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:56 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
GrantCommon Stock 53,686 $0.00 $0.00
Disclosure

SEC source: 0001822629-24-000002 · wk-form4_1708120602.xml · nonDerivative · entry 2

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 483,960

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:56 UTC
Lalwani NikhilDirector · PRESIDENT & CEO
GrantCommon Stock 80,530 $0.00 $0.00
Disclosure

SEC source: 0001822629-24-000002 · wk-form4_1708120602.xml · nonDerivative · entry 1

Lalwani Nikhil · CIK 0001822629 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,274

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:53 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
GrantCommon Stock 8,946 $0.00 $0.00
Disclosure

SEC source: 0001870913-24-000006 · wk-form4_1708120376.xml · nonDerivative · entry 2

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,774

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:53 UTC
Shanmugam MuthusamyDirector · HEAD OF R&D, COO-NOVITIUM OPS
GrantCommon Stock 13,421 $0.00 $0.00
Disclosure

SEC source: 0001870913-24-000006 · wk-form4_1708120376.xml · nonDerivative · entry 1

Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,828

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:50 UTC
Mutz ChristopherHEAD OF RARE DISEASE
GrantCommon Stock 12,526 $0.00 $0.00
Disclosure

SEC source: 0001846487-24-000002 · wk-form4_1708120221.xml · nonDerivative · entry 2

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,923

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:50 UTC
Mutz ChristopherHEAD OF RARE DISEASE
GrantCommon Stock 18,790 $0.00 $0.00
Disclosure

SEC source: 0001846487-24-000002 · wk-form4_1708120221.xml · nonDerivative · entry 1

Mutz Christopher · CIK 0001846487 · HEAD OF RARE DISEASE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,397

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:34 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
GrantCommon Stock 8,946 $0.00 $0.00
Disclosure

SEC source: 0001871002-24-000002 · wk-form4_1708119272.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,314

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:34 UTC
Gassert ChadSVP - CORP. DEV. & STRATEGY
GrantCommon Stock 13,421 $0.00 $0.00
Disclosure

SEC source: 0001871002-24-000002 · wk-form4_1708119272.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,368

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:47 UTC
Marken James G.SVP OPS & PROD DEV
GrantCommon Stock 6,710 $0.00 $0.00
Disclosure

SEC source: 0001579587-24-000002 · wk-form4_1708120015.xml · nonDerivative · entry 2

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,888

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:47 UTC
Marken James G.SVP OPS & PROD DEV
GrantCommon Stock 10,066 $0.00 $0.00
Disclosure

SEC source: 0001579587-24-000002 · wk-form4_1708120015.xml · nonDerivative · entry 1

Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,178

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:38 UTC
Gutwerg OriSVP, GENERICS
GrantCommon Stock 9,842 $0.00 $0.00
Disclosure

SEC source: 0001846478-24-000003 · wk-form4_1708119468.xml · nonDerivative · entry 2

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,520

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:38 UTC
Gutwerg OriSVP, GENERICS
GrantCommon Stock 14,763 $0.00 $0.00
Disclosure

SEC source: 0001846478-24-000003 · wk-form4_1708119468.xml · nonDerivative · entry 1

Gutwerg Ori · CIK 0001846478 · SVP, GENERICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,678

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:30 UTC
Davis KristaSVP, CHIEF HR OFFICER
GrantCommon Stock 8,052 $0.00 $0.00
Disclosure

SEC source: 0001946439-24-000002 · wk-form4_1708119020.xml · nonDerivative · entry 2

Davis Krista · CIK 0001946439 · SVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,718

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.